[PEGASUS or COMPASS? A guide for a wise clinical choice.]

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacotherapy

Background:

• The PEGASUS and COMPASS trials have significantly impacted the management of stable ischemic heart disease (SIHD).
• Patients with SIHD may be eligible for treatments evaluated in both studies, creating a need for clear decision-making tools.
• Current clinical guidelines require nuanced interpretation when considering these advanced therapeutic options.

Discussion:

• This work introduces a practical nomogram to aid clinicians in selecting optimal treatment strategies for SIHD patients.
• The nomogram is based on the inclusion and exclusion criteria of the PEGASUS and COMPASS studies.
• It simplifies the complex decision-making process for patients potentially eligible for multiple treatment pathways.

Key Insights:

• A simple nomogram can effectively guide treatment decisions for stable ischemic heart disease patients.
• The tool integrates key patient characteristics to differentiate between treatment options from major clinical trials.
• Facilitates personalized medicine by aligning patient profiles with evidence-based therapeutic recommendations.

Outlook:

• This nomogram can be integrated into clinical workflows to enhance treatment selection for SIHD.
• Further validation and real-world data will refine the nomogram's utility and applicability.
• Future research may focus on expanding the nomogram to include additional therapeutic modalities or patient subgroups.